Empros Pharma Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
9
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$7.73M
- Investors
-
2
Empros Pharma General Information
Description
Developer of an oral therapy designed to support long-term weight-loss maintenance following incretin-based therapy-induced weight reduction. The company offers a modified-release formulation combining locally active, established drugs such as orlistat and acarbose, enabling adults seeking sustained weight management after initial weight reduction improved tolerability and consistent gastrointestinal support.
Contact Information
Website
www.emprospharma.comCorporate Office
- Nanna Svartz väg 4
- 171 65 Solna
- Sweden
Corporate Office
- Nanna Svartz väg 4
- 171 65 Solna
- Sweden
Empros Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Later Stage VC | 03-May-2023 | $7.73M | Completed | Clinical Trials - Phase 2 | ||
| 4. Later Stage VC | 07-Apr-2019 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC | 01-Jan-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC | 01-Jan-2016 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC | Completed | Product Development |
Empros Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | 50,000 | $53.35 | $53.35 | 1x | $53.35 | 19.21% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Empros Pharma Patents
Empros Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2024519926-A | Reduced rebound effect in subjects treated for overweight or obesity | Pending | 21-May-2021 | ||
| CA-3219508-A1 | Reduced rebound effects in subjects treated for overweight or obesity | Pending | 21-May-2021 | ||
| EP-4340812-A1 | Reduced rebound effects in subjects treated for overweight or obesity | Pending | 21-May-2021 | ||
| US-20250127752-A1 | Reduced rebound effects in subjects treated for overweight or obesity | Pending | 21-May-2021 | ||
| WO-2022243534-A1 | Reduced rebound effects in subjects treated for overweight or obesity | Inactive | 21-May-2021 | A61P3/04 |
Empros Pharma Signals
Empros Pharma Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Flerie | Venture Capital | Minority | ||
| Angel (individual) | Minority |
Empros Pharma FAQs
-
When was Empros Pharma founded?
Empros Pharma was founded in 2013.
-
Where is Empros Pharma headquartered?
Empros Pharma is headquartered in Solna, Sweden.
-
What is the size of Empros Pharma?
Empros Pharma has 9 total employees.
-
What industry is Empros Pharma in?
Empros Pharma’s primary industry is Drug Discovery.
-
Is Empros Pharma a private or public company?
Empros Pharma is a Private company.
-
What is the current valuation of Empros Pharma?
The current valuation of Empros Pharma is .
-
What is Empros Pharma’s current revenue?
The current revenue for Empros Pharma is .
-
How much funding has Empros Pharma raised over time?
Empros Pharma has raised $16.4M.
-
Who are Empros Pharma’s investors?
Flerie and have invested in Empros Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process